Please enable JavaScript to continue using this application.

Compare $AVXL vs $RNA | Chartloom

Compare

$AVXL vs $RNA

Anavex Life Sciences Corp · Atrium Therapeutics Inc

AVXL

Anavex Life Sciences Corp

RNA

Atrium Therapeutics Inc

Compare $AVXL vs $RNA

Comparing Anavex Life Sciences Corp and Atrium Therapeutics Inc

AVXLAnavex Life Sciences Corp

RNAAtrium Therapeutics Inc

AVXLAnavex Life Sciences Corp

Market cap

$138M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-59.5%

52W performance

-84.9%

FCF yield

-21.2%

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVXL

RNA

Detailed metrics comparison

AVXL

Anavex Life Sciences Corp

RNA

Atrium Therapeutics Inc

Market Cap

AVXL$138M

RNA$144M

Enterprise Value

AVXL$20M

RNA$71M

Price

AVXL$1.49

RNA$8.40

P/E Ratio

AVXLN/A

RNAN/A

P/S Ratio

AVXL0.00x

RNA3.48x

EV/Sales

AVXL0.00x

RNA1.73x

EV/EBITDA

AVXL0.00x

RNA0.00x

P/B Ratio

AVXL1.50x

RNA0.63x

P/FCF Ratio

AVXLN/A

RNAN/A

EV/FCF

AVXL-0.67x

RNA-0.89x

PEG Ratio

AVXLN/A

RNAN/A

Forward P/E (NTM)

AVXLN/A

RNAN/A

Forward P/S (NTM)

AVXLN/A

RNAN/A

Revenue (TTM)

AVXL$0

RNA$41M

Revenue Growth (YoY)

AVXLN/A

RNA22.0%

Forward Rev Growth

AVXL377.5%

RNA-94.2%

Gross Margin (TTM)

AVXL0.0%

RNA0.0%

Operating Margin (TTM)

AVXL0.0%

RNA0.0%

EBITDA Margin (TTM)

AVXL0.0%

RNA-215.0%

Net Margin (TTM)

AVXL0.0%

RNA-209.2%

FCF Margin (TTM)

AVXLN/A

RNA-193.4%

Net Income (TTM)

AVXL$-13M

RNA$-86M

FCF (TTM)

AVXL$-29M

RNA$-80M

EPS (TTM)

AVXL-$0.14

RNA-$5.05

ROE (TTM)

AVXL-1143.0%

RNA-4030.0%

ROA (TTM)

AVXL-1072.0%

RNA-5864.0%

ROIC (TTM)

AVXL-1143.0%

RNA-4433.7%

Cash

AVXL$118M

RNA$72M

Debt

AVXL$0

RNA$0

Net Cash/Debt

AVXL$118M

RNA$72M

Current Ratio (TTM)

AVXL15.62x

RNA8.73x

Quick Ratio (TTM)

AVXL15.51x

RNA8.59x

Debt/Equity (TTM)

AVXL0.00x

RNA0.00x

Debt/Assets (TTM)

AVXL0.0%

RNA0.0%

Interest Coverage (TTM)

AVXLN/A

RNAN/A

Net Debt/EBITDA (TTM)

AVXL0.00x

RNA0.00x

Beta

AVXL1.20

RNA1.20

52W Performance

AVXL-84.9%

RNA-82.6%

YTD Performance

AVXL-59.5%

RNA-88.3%

% from 52W High

AVXL-85.0%

RNA-88.5%

% from 52W Low

AVXL3.5%

RNA10.1%

Asset Turnover (TTM)

AVXL0.00x

RNA0.28x

FCF Yield (TTM)

AVXL-21.2%

RNA-55.5%

Earnings Yield (TTM)

AVXL-9.4%

RNA-60.1%

Dividend Yield (TTM)

AVXLN/A

RNAN/A

Rule of 40

AVXL0.0

RNA-171.3

EV/GP/RG

AVXLN/A

RNAN/A

Ticker research

View AVXL research View RNA research

Metric	AVXL Anavex Life Sciences Corp	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$138M	$144M
Enterprise Value	$20M	$71M
Price	$1.49	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.48x
EV/Sales	0.00x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.50x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.67x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$41M
Revenue Growth (YoY)	N/A	22.0%
Forward Rev Growth	377.5%	-94.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-215.0%
Net Margin (TTM)	0.0%	-209.2%
FCF Margin (TTM)	N/A	-193.4%
Net Income (TTM)	$-13M	$-86M
FCF (TTM)	$-29M	$-80M
EPS (TTM)	-$0.14	-$5.05
ROE (TTM)	-1143.0%	-4030.0%
ROA (TTM)	-1072.0%	-5864.0%
ROIC (TTM)	-1143.0%	-4433.7%
Financial Health
Cash	$118M	$72M
Debt	$0	$0
Net Cash/Debt	$118M	$72M
Current Ratio (TTM)	15.62x	8.73x
Quick Ratio (TTM)	15.51x	8.59x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.20
52W Performance	-84.9%	-82.6%
YTD Performance	-59.5%	-88.3%
% from 52W High	-85.0%	-88.5%
% from 52W Low	3.5%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.28x
FCF Yield (TTM)	-21.2%	-55.5%
Earnings Yield (TTM)	-9.4%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View AVXL research	View RNA research

Valuation

P/S Ratio

AVXL

0.00x

RNA

3.48x

EV/FCF

RNA

-0.89x

AVXL

-0.67x

Growth & revenue

Revenue Growth TTM

RNA

22.0%

Forward Revenue Growth

AVXL

377.5%

RNA

-94.2%

Profitability & performance

Gross Margin

AVXL

0.0%

RNA

0.0%

ROE

AVXL

-1143.0%

RNA

-4030.0%

FCF Yield %

AVXL

-21.2%

RNA

-55.5%

52-Week Performance

RNA

-82.6%

AVXL

-84.9%

Detailed metrics comparison

AVXL

Anavex Life Sciences Corp

RNA

Atrium Therapeutics Inc

Market Cap

AVXL$138M

RNA$144M

Enterprise Value

AVXL$20M

RNA$71M

Price

AVXL$1.49

RNA$8.40

P/E Ratio

AVXLN/A

RNAN/A

P/S Ratio

AVXL0.00x

RNA3.48x

EV/Sales

AVXL0.00x

RNA1.73x

EV/EBITDA

AVXL0.00x

RNA0.00x

P/B Ratio

AVXL1.50x

RNA0.63x

P/FCF Ratio

AVXLN/A

RNAN/A

EV/FCF

AVXL-0.67x

RNA-0.89x

PEG Ratio

AVXLN/A

RNAN/A

Forward P/E (NTM)

AVXLN/A

RNAN/A

Forward P/S (NTM)

AVXLN/A

RNAN/A

Revenue (TTM)

AVXL$0

RNA$41M

Revenue Growth (YoY)

AVXLN/A

RNA22.0%

Forward Rev Growth

AVXL377.5%

RNA-94.2%

Gross Margin (TTM)

AVXL0.0%

RNA0.0%

Operating Margin (TTM)

AVXL0.0%

RNA0.0%

EBITDA Margin (TTM)

AVXL0.0%

RNA-215.0%

Net Margin (TTM)

AVXL0.0%

RNA-209.2%

FCF Margin (TTM)

AVXLN/A

RNA-193.4%

Net Income (TTM)

AVXL$-13M

RNA$-86M

FCF (TTM)

AVXL$-29M

RNA$-80M

EPS (TTM)

AVXL-$0.14

RNA-$5.05

ROE (TTM)

AVXL-1143.0%

RNA-4030.0%

ROA (TTM)

AVXL-1072.0%

RNA-5864.0%

ROIC (TTM)

AVXL-1143.0%

RNA-4433.7%

Cash

AVXL$118M

RNA$72M

Debt

AVXL$0

RNA$0

Net Cash/Debt

AVXL$118M

RNA$72M

Current Ratio (TTM)

AVXL15.62x

RNA8.73x

Quick Ratio (TTM)

AVXL15.51x

RNA8.59x

Debt/Equity (TTM)

AVXL0.00x

RNA0.00x

Debt/Assets (TTM)

AVXL0.0%

RNA0.0%

Interest Coverage (TTM)

AVXLN/A

RNAN/A

Net Debt/EBITDA (TTM)

AVXL0.00x

RNA0.00x

Beta

AVXL1.20

RNA1.20

52W Performance

AVXL-84.9%

RNA-82.6%

YTD Performance

AVXL-59.5%

RNA-88.3%

% from 52W High

AVXL-85.0%

RNA-88.5%

% from 52W Low

AVXL3.5%

RNA10.1%

Asset Turnover (TTM)

AVXL0.00x

RNA0.28x

FCF Yield (TTM)

AVXL-21.2%

RNA-55.5%

Earnings Yield (TTM)

AVXL-9.4%

RNA-60.1%

Dividend Yield (TTM)

AVXLN/A

RNAN/A

Rule of 40

AVXL0.0

RNA-171.3

EV/GP/RG

AVXLN/A

RNAN/A

Ticker research

View AVXL research View RNA research

Metric	AVXL Anavex Life Sciences Corp	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$138M	$144M
Enterprise Value	$20M	$71M
Price	$1.49	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.48x
EV/Sales	0.00x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.50x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.67x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$41M
Revenue Growth (YoY)	N/A	22.0%
Forward Rev Growth	377.5%	-94.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-215.0%
Net Margin (TTM)	0.0%	-209.2%
FCF Margin (TTM)	N/A	-193.4%
Net Income (TTM)	$-13M	$-86M
FCF (TTM)	$-29M	$-80M
EPS (TTM)	-$0.14	-$5.05
ROE (TTM)	-1143.0%	-4030.0%
ROA (TTM)	-1072.0%	-5864.0%
ROIC (TTM)	-1143.0%	-4433.7%
Financial Health
Cash	$118M	$72M
Debt	$0	$0
Net Cash/Debt	$118M	$72M
Current Ratio (TTM)	15.62x	8.73x
Quick Ratio (TTM)	15.51x	8.59x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	1.20
52W Performance	-84.9%	-82.6%
YTD Performance	-59.5%	-88.3%
% from 52W High	-85.0%	-88.5%
% from 52W Low	3.5%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.28x
FCF Yield (TTM)	-21.2%	-55.5%
Earnings Yield (TTM)	-9.4%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View AVXL research	View RNA research